Therapeutic options in IgA nephropathy.
IgA nephropathy (IgAN) is a common form of glomerulonephritis that leads to end-stage renal disease at variable rates in 20% to 30% of cases. A rational approach to therapy requires an understanding of pathogenetic mechanisms that are largely unknown. Several therapeutic approaches have been used, generally in uncontrolled trials, aimed at lowering levels of circulating immune complexes, affecting cellular immunity, or removing antigens through dietary restriction. Thus far, no clear-cut beneficial effects are evident. Alternative means of changing glomerular hemodynamics through prevention of harmful mediators await exploration.
Clarkson
A R
AR
Renal Unit, Royal Adelaide Hospital, Australia.
Woodroffe
A J
AJ
Aarons
I A
IA
Thompson
T
T
Hale
G M
GM
D000936:Antigen-Antibody Complex / Q000276:immunology; D002986:Clinical Trials as Topic; D005922:Glomerulonephritis, IGA / Q000628:therapy*; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D011379:Prognosis
D000936:Antigen-Antibody Complex; D007070:Immunoglobulin A